The Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade
Open accessThe DOI matches its Crossref record; 452 of the 457 references it cites were found in a registry or an index.
Abstract
The amyloid-β oligomer (AβO) hypothesis was introduced in 1998. It proposed that the brain damage leading to Alzheimer's disease (AD) was instigated by soluble, ligand-like AβOs. This hypothesis was based on the discovery that fibril-free synthetic preparations of AβOs were potent CNS neurotoxins that rapidly inhibited long-term potentiation and, with time, caused selective nerve cell death (Lambert et al., 1998). The mechanism was attributed to disrupted signaling involving the tyrosine-protein kinase Fyn, mediated by an unknown toxin receptor. Over 4,000 articles concerning AβOs have been published since then, including more than 400 reviews. AβOs have been shown to accumulate in an AD-dependent manner in human and animal model brain tissue and, experimentally, to impair learning and memory and instigate major facets of AD neuropathology, including tau pathology, synapse deterioration and loss, inflammation, and oxidative damage. As reviewed by Hayden and Teplow in 2013, the AβO hypothesis "has all but supplanted the amyloid cascade." Despite the emerging understanding of the role played by AβOs in AD pathogenesis, AβOs have not yet received the clinical attention given to amyloid plaques, which have been at the core of major attempts at therapeutics and diagnostics but are no longer regarded as the most pathogenic form of Aβ. However, if the momentum of AβO research continues, particularly efforts to elucidate key aspects of structure, a clear path to a successful disease modifying therapy can be envisioned. Ensuring that lessons learned from recent, late-stage clinical failures are applied appropriately throughout therapeutic development will further enable the likelihood of a successful therapy in the near-term.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig.1 AβOs, not Aβ monomers or fibrils, instigate the neuron damage leading to dementia. Following cleavage from the membrane, Aβ peptides aggregate to form AβOs, some of which further aggregate to fibrils and some of which instigate the neuron damage leading to dementia. Reprinted with Jannis Productions permissions from the “Progress Report on Alzheimer’s Disease 2004-2005” (ed. AB Rodgers), NIH Publication Number: 05-5724. Digital images produced by Stacy Jannis and Rebekah Fredenburg of Jannis Productions [455].](https://figures.cochat.ai/paper-figures/f6b42a17775e4881b942c99d83b0c0fa/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-1.jpg)
![Fig.2 AβOs instigate multiple facets of AD-neuropathology. Observed in various culture and animal models. Reprinted by permission from Springer Nature: Acta Neuropathol, 129(2): 183-206, “Amyloid beta oligomers in Alzheimer’s disease pathogenesis, treatment, and diagnosis” by Viola KL and Klein WL. Copyright 2015 Springer Nature [200].](https://figures.cochat.ai/paper-figures/4c12da5f31934b84a9263cc86d9b1ffd/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-2.jpg)

![Fig.4 AβOs can be divided into two classes based on their temporal, spatial, and structural relationships to amyloid plaques as well as their ability to cause memory dysfunction. Type 1 AβOs (aka “peak 1” or HMW) are thought to be associated with memory impairment, while type 2 AβOs (aka “peak 2” or LMW) are not. Only type 2 AβOs are associated with amyloid plaques. Reprinted from “Quaternary Structure Defines a Large Class of Amyloid-beta Oligomers Neutralized by Sequestration” by Liu P, Reed MN, Kotilinek LA, Grant MK, Forster CL, Qiang W, Shapiro SL, Reichl JH, Chiang AC, Jankowsky JL, Wilmot CM, Cleary JP, Zahs KR, and Ashe KH. This was published in Cell Rep, 2015, 11(11): 1760-1771, under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License (CC BY NC ND) https://creativecommons.org/licenses/by-nc-nd/4.0/ [119].](https://figures.cochat.ai/paper-figures/c5448ccd6aa14c24a04007d7a6986c4e/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-4.jpg)
![Fig.5 Only high-molecular weight AβOs are capable of binding cultured hippocampal neurons. Synthetic AβOs were divided into high and low molecular weight populations using 50 kDa molecular weight cutoff ultrafiltration (A-B) or size exclusion chromatography (D-F) and incubated with cultured hippocampal neurons. Only high-molecular weight AβOs bind neurons (A, E); no binding of low-molecular weight AβOs was evident (B, F). Scale bar = 40μm. Reprinted from “Synaptic targeting by Alzheimer’s-related amyloid beta oligomers” by Lacor PN, Buniel MC, Chang L, Fernandez SJ, Gong Y, Viola KL, Lambert MP, Velasco PT, Bigio EH, Finch CE, Krafft GA, and Klein WL. This was published in J Neurosci, 2004, 24(45): 10191-10200, copyright 2004; permission conveyed through Copyright Clearance Center, Inc. [16].](https://figures.cochat.ai/paper-figures/16de889766c74140a8a5dc196a8cc4d2/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-5.jpg)
![Fig.6 PrPc mediates AβO toxicity through mGluR5, Fyn kinase, and NMDARs. Downstream consequences of the pathway include calcium dyshomeostasis, tau hyperphosphorylation, and synaptic dysfunction and loss. Reprinted from “Fyn kinase inhibition as a novel therapy for Alzheimer’s disease” by Nygaard HB, van Dyck CH, and Strittmater SM. This was published in Alzheimers Res Ther, 2014, 6(1): 8, under the terms of the Creative Commons Attribution License (CC BY) [227].](https://figures.cochat.ai/paper-figures/f727ef34b3b345d8b849289bdb182350/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-6.jpg)
![Fig.7 AβOs induce membrane re-distribution of NKAα3 subunit resulting its downregulation and excessive Ca++ buildup. A hypothesized early event in AβO-induced neuronal damage is binding to NKAα3 on neuronal membranes, causing restructuring of the NKAα3 docking station into toxic clusters of membrane proteins. Ultimately, this results in downregulation of NKAα3 on the neuronal surface and buildup of toxic Ca++. Adapted and reprinted from “Alzheimer’s Toxic Amyloid Beta Oligomers: Unwelcome Visitors to the Na/K ATPase alpha3 Docking Station” by DiChiara T, DiNunno N, Clark J, Bu RL, Cline EN, Rollins MG, Gong Y, Brody DL, Sligar SG, Velasco PT, Viola KL, and Klein WL. This was published in Yale J Biol Med, 2017, 90(1): 45-61, under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License (CC BY NC ND) https://creativecommons.org/licenses/by-nc-nd/4.0/ [199].](https://figures.cochat.ai/paper-figures/bd05d1a512054c909e16e461e4020c7c/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-7.jpg)
![Fig.8 A cumulative hypothesis for the development of sporadic AD. From De Felice, sporadic AD is hypothesized to be the result of the cumulative impact over a life-time of injuries to the brain and peripheral organs that results in increased AβO levels. Reprinted from “Alzheimer’s disease and insulin resistance: translating basic science into clinical applications” by De Felice FG. This was published in JClin Invest, 2013, 123(2): 531-539, under Free access [322].](https://figures.cochat.ai/paper-figures/24020b5bf03e43718e18004cdfcd4325/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-8.jpg)
![Fig.9 Putative therapeutic targets of the AβO pathogenic cascade. Including: 1) AβOs themselves; 2) AβO receptors; 3) signaling pathways; or 4) downstream effectors such as tau. Reprinted with permission of PNAS from “Toward a unified therapeutics approach targeting putative amyloid-beta oligomer receptors” by Overk CR and Masliah E. This was published in Proc Natl Acad Sci U S A, 2014, 111(38): 13680-13681 [392].](https://figures.cochat.ai/paper-figures/fd1348f91c8947ff93496ee3a5d93873/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-9.jpg)
![Fig.10 Mechanisms of Aβ-targeting phase III drugs in AD clinical trials. Drugs inhibiting AβO formation (A) or downstream consequences of toxic AβOs (B). Reprinted from “Alzheimer’s disease drug development pipeline: 2017” by Cummings J, Garam L, Mortsdorf T, Ritter A, and Zhong K. This was published in Alzheimers Dementia (N Y), 2017, 3(3): 367-384 [393], under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License (CC BY NC ND) https://creativecommons.org/licenses/by-nc-nd/4.0/) [393].](https://figures.cochat.ai/paper-figures/3fe1a59ed5324adab364ba96901a832d/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-10.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Soluble Aβ oligomers are the primary neurotoxic substances,131–133”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [131]
The cited source says what the claim attributes to it.
In the citing paper
“Misfolded Aβ and tau proteins accumulate in the AD brain in a neurodegenerative cascade leading to cognitive decline and dementia [4,5,6,7,8,9].”
From Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies (2023) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“The Aβ oligomer hypothesis, supported by in vitro, in vivo, and ex vivo models, points to the toxic Aβ oligomers rather than amyloid plaques as key players in AD pathogenesis [4,5,6,7].”
From Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies (2023) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“Elevated levels of oligomers have been associated with AD, as they are found in AD brains and are considered the most toxic and pathogenic form of Aβ [4,5,6,7,18].”
From Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies (2023) · cites this paper as [6]
In the citing paper
“The alternative “Aβ oligomer hypothesis”, supported by in vitro, in vivo, and ex vivo models, points to the toxic Aβ oligomers (AβO)s rather than amyloid plaques as key players in AD pathogenesis [79,80,81].”
From Role of Oxidative Damage in Alzheimer’s Disease and Neurodegeneration: From Pathogenic Mechanisms to Biomarker Discovery (2021) · cites this paper as [80]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
4 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769
RetractedLarson, M., Sherman, M. A., Amar, F., Nuvolone, M., Schneider, J. A., Bennett, D. A., Aguzzi, A., & Lesné, S. E. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.1858-12.2012 · Cited by 277
RetractedRETRACTED: Cognitive effects of cell-derived and synthetically derived Aβ oligomers
Reed, M. N., Hofmeister, J. J., Jungbauer, L. M., Welzel, A. T., Yu, C., Sherman, M. A., Lesné, S., LaDu, M. J., Walsh, D. M., Ashe, K. H., et al. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.11.007 · Cited by 136
RetractedAmar, F., Sherman, M. A., Rush, T., Larson, M. E., Boyle, G. E., Liu, C., Götz, J., Buisson, A., & Lesné, S. (2017) · Science Signaling · doi:10.1126/scisignal.aal2021 · Cited by 118
RetractedAmyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
Amyloid plaque core protein in Alzheimer disease and Down syndrome.
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4245 · Cited by 4,431
Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397
Meta-Analysis of 74,046 Individuals Identifies 11 New Susceptibility Loci for Alzheimer’s Disease
(EADI), E. A. D. I., Lambert, J.-C., (GERAD), G. A. E. R. I. A. D., Alzheimer's Disease Genetic Consortium (ADGC), (CHARGE), C. F. H. A. A. R. I. G. E., Ibrahim-Verbaas, C. A., Harold, D., Naj, A. C., Sims, R., Bellenguez, C., et al. (2013) · Nature Genetics · doi:10.1038/ng.2802 · Cited by 4,336
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291
Research works printed but not linked: 4
- Meilandt, 2017, Characterization of the selective in vivo and in vitro binding properties of crenezumab: Insights into crenezumab’s unique mechanism of action, J Prev Alzheimers Dis, 4, 293
- Schneider, 2017, The anti-AB oligomer drug CT1812 for Alzheimer’s: Phase 1B/2A safety trial outcomes, J Prev Alzheimers Dis, 4, 317
- Catalano, 2017, Biomarker outcomes from the phase 1b/2a safety trial of the anti-AB oligomer drug CT1812 in Alzheimer’s patients, J Prev Alzheimers Dis, 4, 401
- Leslie, 2017, Phase II study to assess safety and target engagement of AMX0035, a novel combination therapy, in Alzheimer’s disease, Neurotherapeutics, 14, 825
Cited by
Items 301–400 of 867
Rotor-Tuning Boron Dipyrromethenes for Dual-Functional Imaging of Aβ Oligomers and Viscosity
Wang, Y., Yang, J., Chen, Q., Su, J., Shi, W., Zhang, L., Xia, C., & Yan, J. (2022) · ACS Applied Bio Materials · doi:10.1021/acsabm.2c00335 · Cited by 18
Lessard, E., Rennie, K., Haqqani, A. S., Ling, B., Whitfield, J., Paradis, A., Araujo, J. A., Yoganathan, N., Gillard, J. W., Stanimirovic, D. B., et al. (2022) · Pharmaceutical Research · doi:10.1007/s11095-022-03285-z · Cited by 22
Light, Water, and Melatonin: The Synergistic Regulation of Phase Separation in Dementia
Loh, D., & Reiter, R. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065835 · Cited by 12
Review of triazole scaffolds for treatment and diagnosis of Alzheimer's disease
Li, Q., Qi, S., Liang, J., Tian, Y., He, S., Liao, Q., Xing, S., Han, L., & Chen, X. (2023) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2023.110623 · Cited by 20
Kreutzer, A. G., Parrocha, C. M. T., Haerianardakani, S., Guaglianone, G., Nguyen, J. T., Diab, M. N., Yong, W. H., Perez-Rosendahl, M. A., Head, E., & Nowick, J. S. (2023) · ACS Central Science · doi:10.1021/acscentsci.3c00592 · Cited by 21
The epididymal amyloid matrix: structure and putative functions
Cornwall, G. A., Do, H. Q., Hewetson, A., Muthusubramanian, A., & Myers, C. (2019) · Andrology · doi:10.1111/andr.12586 · Cited by 19
Unraveling Alzheimer’s Disease Using Drosophila
Yeates, C. J., Sarkar, A., Kango‐Singh, M., & Singh, A. (2019) · Springer eBooks · doi:10.1007/978-981-13-2218-1_9 · Cited by 24
Cao, Y., Tang, X. L., Miao, Y., & Han, W. (2020) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.12.008 · Cited by 23
Qiang, W., Doherty, K. E., Klees, L. M., & Tobin-Miyaji, Y. J. (2020) · The Journal of Physical Chemistry Letters · doi:10.1021/acs.jpclett.0c01967 · Cited by 18
Soto‐Mercado, V., Mendivil‐Perez, M., Jiménez-Del-Río, M., & Velez‐Pardo, C. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-201045 · Cited by 19
From reaction kinetics to dementia: A simple dimer model of Alzheimer’s disease etiology
Lindstrom, M. R., Chavez, M. B., Gross-Sable, E. A., Hayden, E. Y., & Teplow, D. B. (2021) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1009114 · Cited by 23
The oxidatively damaged DNA and amyloid-β oligomer hypothesis of Alzheimer's disease
Sanders, O. D., Rajagopal, L., & Rajagopal, J. A. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2021.08.019 · Cited by 21
Thiophene‐Based Dual Modulators of Aβ and Tau Aggregation
Ramesh, M., Acharya, A., Murugan, N. A., Ila, H., & Govindaraju, T. (2021) · ChemBioChem · doi:10.1002/cbic.202100383 · Cited by 21
Wakeman, D. R., Weed, M. R., Perez, S. E., Cline, E. N., Viola, K. L., Wilcox, K. C., Moddrelle, D. S., Nisbett, E. Z., Kurian, A., Bell, A., et al. (2022) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12800 · Cited by 19
Self-citationRole of phosphatidylserine in amyloid-beta oligomerization at asymmetric phospholipid bilayers
Robinson, J., Sarangi, N. K., & Keyes, T. E. (2022) · Physical Chemistry Chemical Physics · doi:10.1039/d2cp03344e · Cited by 19
Putative Structures of Membrane-Embedded Amyloid β Oligomers
Sepehri, A., & Lazaridis, T. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00535 · Cited by 18
Experimental approaches for altering the expression of Abeta‐degrading enzymes
Loeffler, D. A. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15762 · Cited by 20
Resveratrol Sustains Insulin-Degrading Enzyme Activity toward Aβ42
Krasinski, C. A., Ivancic, V. A., Zheng, Q., Spratt, D. E., & Lazo, N. D. (2018) · ACS Omega · doi:10.1021/acsomega.8b01913 · Cited by 19
Effects of N-Terminal Residues on the Assembly of Constrained β-Hairpin Peptides Derived from Aβ
Samdin, T. D., Wierzbicki, M., Kreutzer, A. G., Howitz, W. J., Valenzuela, M., Smith, A., Sahrai, V., Truex, N. L., Klun, M., & Nowick, J. S. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.0c05186 · Cited by 18
Plexin-A4 mediates amyloid-β–induced tau pathology in Alzheimer’s disease animal model
Chung, S., Yang, J., Kim, H. J., Hwang, E. M., Lee, W., Suh, K. Y., Choi, H., & Mook‐Jung, I. (2021) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2021.102075 · Cited by 20
Mockett, B. G., & Ryan, M. M. (2022) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2022.05.014 · Cited by 19
Somatic Mutations and Alzheimer’s Disease
Downey, J. S., Lam, J. C. K., Li, V. O. K., & Gozes, I. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220643 · Cited by 20
Probing differences among Aβ oligomers with two triangular trimers derived from Aβ
Kreutzer, A. G., Guaglianone, G., Yoo, S., Parrocha, C. M. T., Ruttenberg, S. M., Malonis, R. J., Tong, K., Lin, Y.-F., Nguyen, J. T., Howitz, W. J., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2219216120 · Cited by 18
The molecular spectrum of amyloid‐beta (Aβ) in neurodegenerative diseases beyond Alzheimer's disease
Ichimata, S., Yoshida, K., Li, J., Rogaeva, E. A., Lang, A. E., & Kovács, G. G. (2023) · Brain Pathology · doi:10.1111/bpa.13210 · Cited by 18
Fagla, B. M., & Buhimschi, I. A. (2024) · Molecules · doi:10.3390/molecules29030610 · Cited by 18
Systemic Immune Dyshomeostasis Model and Pathways in Alzheimer’s Disease
Talwar, P., Kushwaha, S. S., Gupta, R., & Agarwal, R. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00290 · Cited by 18
Falco, A. D., Kincheski, G. C., Atrián‐Blasco, E., Hureau, C., Ferreira, S. T., & Rey, N. A. (2020) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000578 · Cited by 19
Triaca, V., Ruberti, F., & Canu, N. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-74046-7_10 · Cited by 20
Araki, W., & Kametani, F. (2022) · Antioxidants · doi:10.3390/antiox11010132 · Cited by 22
Durell, S. R., Kayed, R., & Guy, H. R. (2022) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.26301 · Cited by 16
Modelling Alzheimer's disease using human brain organoids: current progress and challenges
Yanakiev, M., Soper, O., Berg, D. A., & Kang, E. (2022) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2022.40 · Cited by 18
Valencia‐Olvera, A. C., Balu, D., Bellur, S., McNally, T. P., Saleh, Y., Pham, D., Ghura, S., York, J. M., Johansson, J. O., LaDu, M. J., et al. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01353-z · Cited by 19
Olsen, I., & Singhrao, S. K. (2019) · Current Oral Health Reports · doi:10.1007/s40496-019-0212-8 · Cited by 18
Kumari, A., Somvanshi, P., & Grover, A. (2020) · RSC Advances · doi:10.1039/d0ra00429d · Cited by 16
Liu, D., Lü, S., Zhang, L., Huang, Y., Ji, M., Sun, X., Liu, X., & Liu, R. (2020) · Vaccines · doi:10.3390/vaccines8030351 · Cited by 16
Gan, K. J., Akram, A., Blasius, T. L., Ramser, E. M., Budaitis, B. G., Gabrych, D. R., Verhey, K. J., & Silverman, M. A. (2020) · eNeuro · doi:10.1523/eneuro.0176-20.2020 · Cited by 16
Bitencourt, A. L. B., de Campos, R. M., Cline, E. N., Klein, W. L., & Sebollela, A. S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21238920 · Cited by 21
Self-citationTrumbore, C. N. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-201025 · Cited by 17
Zhang, M., Wu, Q., Zhao, R., Yao, X., Du, X., Liu, Q., Lv, G., & Xiao, S. (2021) · Food & Function · doi:10.1039/d1fo01306h · Cited by 18
Zhang, X., Huai, Y., Cai, J., Song, C., & Zhang, Y. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.12.014 · Cited by 17
Force clamp approach for characterization of nano-assembly in amyloid beta 42 dimer
Maity, S., & Lyubchenko, Y. L. (2019) · Nanoscale · doi:10.1039/c9nr01670h · Cited by 16
Medin Oligomer Membrane Pore Formation: A Potential Mechanism of Vascular Dysfunction
Younger, S., Jang, H., Davies, H. A., Niemiec, M., Garcia, J. G. N., Nussinov, R., Migrino, R. Q., Madine, J., & Arce, F. T. (2020) · Biophysical Journal · doi:10.1016/j.bpj.2020.04.026 · Cited by 16
Yook, Y., Lee, K. Y., Kim, E. Y., Lizarazo, S., Yu, X., & Tsai, N. (2024) · EMBO Reports · doi:10.1038/s44319-024-00090-0 · Cited by 17
Jeong, Y.-M., Lee, J. G., Cho, H.-J., Lee, W. S., Jeong, J., & Lee, J.-S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111883 · Cited by 14
Plachez, C., Tsytsarev, V., Zhao, S., & Erzurumlu, R. S. (2022) · Neuroscience · doi:10.1016/j.neuroscience.2022.12.013 · Cited by 18
Paul, S., Jeništová, A., Vosough, F., Berntsson, E., Mörman, C., Jarvet, J., Gräslund, A., Wärmländer, S. K. T. S., & Barth, A. (2023) · Communications Chemistry · doi:10.1038/s42004-023-00955-w · Cited by 18
Blömeke, L., Rehn, F., Pils, M., Kraemer‐Schulien, V., Cousin, A., Kutzsche, J., Bujnicki, T., Freiesleben, S. D., Schneider, L., Preis, L., et al. (2024) · Communications Medicine · doi:10.1038/s43856-024-00690-w · Cited by 15
Aβ and the dementia syndrome: Simple versus complex perspectives
Hunter, S., Smailagic, N., & Brayne, C. (2018) · European Journal of Clinical Investigation · doi:10.1111/eci.13025 · Cited by 15
Lee, J., Choi, Y. K., Chung, S., Yoon, D. H., Choi, S. H., Kang, S. M., Seo, D., & Park, K. (2020) · Diagnostics · doi:10.3390/diagnostics10040237 · Cited by 15
Schachner, L. F., Tran, D. P., Lee, A. S., McGee, J. P., Jooß, K., Durbin, K. R., Seckler, H. S., Adams, L. M., Cline, E. N., Melani, R. D., et al. (2021) · International Journal of Mass Spectrometry · doi:10.1016/j.ijms.2021.116591 · Cited by 16
Self-citationNeutrophil Granule Proteins Inhibit Amyloid Beta Aggregation and Neurotoxicity
Kasus‐Jacobi, A., Washburn, J. L., Land, C. A., & Pereira, H. A. (2021) · Current Alzheimer Research · doi:10.2174/1567205018666210823095044 · Cited by 15
Amyloid-beta Targeted Therapeutic Approaches for Alzheimer’s Disease: Long Road Ahead
Dai, Y., Lei, C., Zhang, Z., Qi, Y., Lao, K., & Gou, X. (2022) · Current Drug Targets · doi:10.2174/1389450123666220421124030 · Cited by 16
Carvalho, A., Barbosa, B. M., Flores, J. S., Gonçalves, P. D. C., Diniz, R., Cordeiro, Y., Fernández, C. O., Cukierman, D. S., & Rey, N. A. (2022) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2022.112033 · Cited by 17
Nakatsu, D., Kunishige, R., Taguchi, Y., Shinozaki‐Narikawa, N., Osaka, K., Yokomizo, K., Ishida, M., Takei, S., Yamasaki, S., Hagiya, K., et al. (2023) · Stem Cell Reports · doi:10.1016/j.stemcr.2023.01.004 · Cited by 16
Chatanaka, M. K., Sohaei, D., Diamandis, E. P., & Prassas, I. (2023) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2023.2187342 · Cited by 15
Ichimata, S., Martínez-Valbuena, I., Lee, S., Li, J., Karakani, A. M., & Kovács, G. G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411596 · Cited by 15
Ivancic, V. A., Krasinski, C. A., Zheng, Q., Meservier, R. J., Spratt, D. E., & Lazo, N. D. (2018) · Bioscience Reports · doi:10.1042/bsr20181416 · Cited by 15
Hydrogen Peroxide Modifies Aβ–Membrane Interactions with Implications for Aβ40 Aggregation
Pilkington, A. W., Donohoe, G. C., Akhmedov, N. G., Ferrebee, T., Valentine, S. J., & Legleiter, J. A. (2019) · Biochemistry · doi:10.1021/acs.biochem.9b00233 · Cited by 20
Ahyayauch, H., Masserini, M., Goñi, F. M., & Alonso, A. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.11.112 · Cited by 15
Selkoe, D. J. (2018) · Biochemistry · doi:10.1021/acs.biochem.8b00985 · Cited by 15
Dopamine, sleep, and neuronal excitability modulate amyloid-β–mediated forgetting in Drosophila
Kaldun, J. C., Lone, S. R., Camps, A. M. H., Fritsch, C., Widmer, Y. F., Stein, J. V., Tomchik, S. M., & Sprecher, S. G. (2021) · PLoS Biology · doi:10.1371/journal.pbio.3001412 · Cited by 16
Ng, A. N., Salter, E. W., Georgiou, J., Bortolotto, Z. A., & Collingridge, G. L. (2023) · iScience · doi:10.1016/j.isci.2023.108412 · Cited by 18
A β-barrel-like tetramer formed by a β-hairpin derived from Aβ
Samdin, T. D., Jones, C. R., Guaglianone, G., Kreutzer, A. G., Freites, J. A., Wierzbicki, M., & Nowick, J. S. (2023) · Chemical Science · doi:10.1039/d3sc05185d · Cited by 16
Chimeric antigen receptors discriminate between tau and distinct amyloid-beta species
Siebrand, C. J., Bergo, N. J., Lee, S., Andersen, J. K., & Walton, C. C. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06572-6 · Cited by 15
he amyloid hypothesis of Alzheimer's disease: past and present, hopes and disappointments
Litvinenko, I., Emelin, А. Y., Lobzin, V. Y., Kolmakova, K. A., Naumov, K. M., Lupanov, I. A., Киливаева, Г. А., & Alizade, M. (2019) · Neurology neuropsychiatry Psychosomatics · doi:10.14412/2074-2711-2019-3-4-10 · Cited by 14
Zhang, X., Ma, X., Gan, T., Shi, Y., Wang, Y., & Liu, Q. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00662 · Cited by 14
Cali, M. P., Pereira, L. M. B., Teodoro, M. D., Sellani, T. A., Rodrigues, E. G., & Carlos, R. M. (2020) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2020.111314 · Cited by 16
Degradation Products of Amyloid Protein: Are They The Culprits?
Zaretsky, D. V., & Zaretskaia, M. V. (2020) · Current Alzheimer Research · doi:10.2174/1567205017666201203142103 · Cited by 15
Zhang, X., Meng, Y., Yan, X., Liu, S., Wang, G., & Cao, Y. (2021) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2021.05.019 · Cited by 15
Salimi, A., Li, H., & Lee, J. Y. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.06.078 · Cited by 14
Grochowska, K. M., Bär, J., Gomes, G. M., Kreutz, M. R., & Karpova, A. (2021) · Frontiers in Synaptic Neuroscience · doi:10.3389/fnsyn.2021.787494 · Cited by 15
The calcium-free form of atorvastatin inhibits amyloid-β(1–42) aggregation in vitro
Nedaei, H., Rezaei‐Ghaleh, N., Giller, K., Becker, S., Karami, L., Moosavi‐Movahedi, A. A., Griesinger, C., & Moosavi‐Movahedi, A. A. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.101662 · Cited by 16
Alves, S. S., da Silva-Júnior, R. M. P., Delfino-Pereira, P., Pereira, M. G. A. G., Vasconcelos, I. C., Schwaemmle, H., Mazzei, R. F., Carlos, M. L., Espreáfico, E. M., Tedesco, A. C., et al. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-02810-w · Cited by 16
N‑terminal Domain of Amyloid‑β Impacts Fibrillation and Neurotoxicity
Shi, J., Li, H., Liu, H., Zhu, L., Guo, Y.-B., Pei, J., An, H., Li, Y., Li, S.-D., Zhang, Z., et al. (2022) · ACS Omega · doi:10.1021/acsomega.2c04583 · Cited by 14
Nikolaeva, N. S., Yandulova, E. Y., Aleksandrova, Y. R., Starikov, A. S., & Неганова, М. Е. (2022) · Acta Naturae · doi:10.32607/actanaturae.11723 · Cited by 15
Mitroshina, Е. V., Pakhomov, A. M., Krivonosov, M., Yarkov, R. S., Gavrish, M. S., Shkirin, A. V., Ivanchenko, M., & Vedunova, M. V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415928 · Cited by 17
Habashi, M., Chauhan, P. S., Vutla, S., Senapati, S., Diachkov, M., El‐Husseini, A., Guérin, B., Lubell, W. D., & Rahimipour, S. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c02049 · Cited by 18
Whiteaker, P., & George, A. A. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106743 · Cited by 15
Deshpande, P., Chen, C., Chimata, A. V., Li, J., Sarkar, A., Yeates, C. J., Chen, C., Kango‐Singh, M., & Singh, A. (2024) · Cell Death and Disease · doi:10.1038/s41419-023-06361-3 · Cited by 17
Hu, Z., Cruceta, L., Zhang, S., Sun, Y. P., & Qiang, W. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00341 · Cited by 15
Bartley, S. C., Proctor, M. T., Xia, H., Ho, E., Kang, D. S., Schuster, K. H., Bicca, M. A., Seckler, H. S., Viola, K. L., Patrie, S. M., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042208 · Cited by 14
Self-citationAhyayauch, H., de la Arada, I., Masserini, M., Arrondo, J. L. R., Goñi, F. M., & Alonso, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051674 · Cited by 14
A Chronological Review of Potential Disease-Modifying Therapeutic Strategies for Alzheimer’s Disease
Ettcheto, M., Busquets, O., Espinosa-Jiménez, T., Verdaguer, E., Auladell, C., & Camins, A. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200211121416 · Cited by 13
Simulations of cross-amyloid aggregation of amyloid-β and islet amyloid polypeptide fragments
Kawecki, G., King, K. M., Cramer, N. A., Bevan, D. R., & Brown, A. M. (2022) · Biophysical Journal · doi:10.1016/j.bpj.2022.05.007 · Cited by 17
Yu, T.-G., Cha, J. S., Kim, G., Sohn, Y., Yoo, Y., Kim, U., Song, J., Cho, H., & Kim, H. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01438-6 · Cited by 18
Ranganathan, R., Sapozhnikov, G., Wang, N., Li, S., & Song, Y. (2023) · Translational Medicine of Aging · doi:10.1016/j.tma.2023.06.004 · Cited by 14
Holcombe, B., Foes, A., Banerjee, S., Yeh, K. L., Wang, S. J., Bhargava, R., & Ghosh, A. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00400 · Cited by 14
Reed, A. L., Mitchell, W., Alexandrescu, A. T., & Alder, N. N. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2023.1263420 · Cited by 13
A turn for the worse: Aβ β-hairpins in Alzheimer’s disease
Ruttenberg, S. M., & Nowick, J. S. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117715 · Cited by 15
Liu, Z., Cheng, L., Cao, W., Shen, C., Qiu, Y., Li, C., Xiong, Y., Yang, S., Chen, Z., Yin, X., et al. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.135826 · Cited by 14
Lee, W. J., Ham, S. A., Lee, G. H., Choi, M., Yoo, H., Paek, K. S., Lim, D., Hong, K., Hwang, J. S., & Seo, H. G. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14715 · Cited by 14
Khan, M. I., Shin, J. H., Kim, M. Y., Shin, T. S., & Kim, J. D. (2020) · Molecules · doi:10.3390/molecules25102334 · Cited by 13
Madhu, P., Das, D., & Mukhopadhyay, S. (2021) · Physical Chemistry Chemical Physics · doi:10.1039/d0cp06456d · Cited by 15
Cretin, B., Bousiges, O., Hautecloque, G., Philippi, N., Blanc, F., Bitonto, L. D., Martin‐Hunyadi, C., & Sellal, F. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.623777 · Cited by 14
Stepanchuk, A. A., Barber, P. A., Lashley, T., Joseph, J. T., & Stys, P. K. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105540 · Cited by 13
Noninvasive Diagnostics of Renal Amyloidosis: Current State and Perspectives
Fedotov, S. A., Khrabrova, M. S., Anpilova, A., Dobronravov, V., & Rubel, A. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012662 · Cited by 19
Oligomer Formation by Amyloid-β42 in a Membrane-Mimicking Environment in Alzheimer’s Disease
Rosenberry, T. L., Zhou, H., Stagg, S. M., & Paravastu, A. K. (2022) · Molecules · doi:10.3390/molecules27248804 · Cited by 13
Chen, X., Sawa, M., Becker, A., Karachentsev, D., Zuo, X., Rynearson, K. D., Tanzi, R. E., & Mobley, W. C. (2023) · Annals of Neurology · doi:10.1002/ana.26659 · Cited by 13
Wang, S., Meng, F., Hao, R., Wang, C., & Li, F. (2019) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2019.183108 · Cited by 13
Modulation of tau protein aggregation using ‘Trojan’ sequences
Pandey, G., Morla, S., Kumar, S., & Ramakrishnan, V. (2020) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2020.129569 · Cited by 13
Metadata
- Authors
- Cline, E. N., Bicca, M. A., Viola, K. L., & Klein, W. L.
- Affiliations
- Northwestern University (US)
- Department of Neurobiology, Cognitive Neurology and Alzheimer’s Disease Center, International Institute for Nanotechnology, and Chemistry of Life Processes Institute, Northwestern University, Evanston, IL, USA
- Corresponding author
- Klein, William L.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2018-06-12
- Volume
- 64
- Issue
- s1
- Pages
- S567-S610
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- PMC
- PMC6004937
- OpenAlex
- W2809078375
- Cited by
- 870
- References
- 457
- Citations by year
- 2026: 72 · 2025: 109 · 2024: 99 · 2023: 133 · 2022: 123 · 2021: 123 · 2020: 119 · 2019: 74 · 2018: 17
- FWCI
- 10.99
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Alzheimer s Disease (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Institute on Aging (R41AG054337, T32AG020506)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- amyloid-beta oligomers, Alzheimer's disease
- MeSH terms
- Alzheimer Disease, Animals, Humans, Models, Neurological, Amyloid beta-Peptides
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.